Counterfeit Medicine: Should Parallel Import of Medicine be Banned in Malaysia?
Abstract
Parallel import is the activity of importing and reselling products without the patent holder's permission. Parallel importation is legal on the principle of flexibility found in the TRIPS Agreement under the provisions of Article 6 (exhaustion of intellectual property) and Article 8 (scope of public health interest) to guarantee access to medicinal products. However, whether parallel imports are regulated or otherwise by countries is provided for under Paragraph 5(d) of the Doha Declaration on TRIPS and Public Health 2001 which states that member countries are given the freedom to determine their exhaustion regime. This explains why there are countries that allow parallel trade in medicines whereas some do not. The main reason for some countries (including Malaysia) not allowing parallel imports is the belief that parallel importation is associated with the penetration of counterfeit medicines into the market. Therefore, this paper aims to determine the relationship between parallel imports and incidents of counterfeit medicinal products in the country. The discussions include measures that can be implemented to ensure the quality, safety, and efficacy of parallel import drug products are not compromised. In conclusion, findings from this study suggest that the parallel import of medicine is not related to the increase in cases of counterfeit medicine, hence should not be banned in Malaysia.
Keywords
Full Text:
PDFReferences
Aguiar, E., & Ernest, K. (2020, January). Savings from parallel imports in Europe. Affordable Medicines Europe. https://affordablemedicines.eu/portfolio-item/savings-from-parallel-imports-in-europe/
Ahmad, R. (2002). Parallel importation and compulsory licensing-impact on drug prices in Malaysia. Master’s thesis, Universiti Malaysia Sarawak.
Bakker-'t Hart, I. M. E., Ohana, D., & Venhuis, B. J. (2021). Current challenges in the detection and analysis of falsified medicines. Journal of Pharmaceutical and Biomedical Analysis, 197, 113948. https://doi.org/10.1016/j.jpba.2021.113948
Bengtsson, M. (2016). How to plan and perform a qualitative study using content analysis. Nursing Plus Open, 2, 8–14. https://doi.org/10.1016/j.npls.2016.01.001
Bolla, A. S., Patel, A. R., & Priefer, R. (2020). The silent development of counterfeit medications in developing countries – A systematic review of detection technologies. International Journal of Pharmaceutics, 587, 119702. https://doi.org/10.1016/j.ijpharm.2020.119702
Bottoni, P., & Caroli, S. (2019). Fake pharmaceuticals: A review of current analytical approaches. Microchemical Journal, 149. https://doi.org/10.1016/j.microc.2019.104053
Director of Pharmaceutical Services Programme Directive. (2022). Implementation of the Pharmaceutical Track & Trace Pilot Project. Accessed July 7, 2024, from https://www.npra.gov.my/easyarticles/images/users/1047/Direktif/Pelaksanaan-Projek-Rintis-Pharmaceutical-Track--Trace.pdf
Drug and Cosmetic Control Regulations 1984.
ECA Academy Website. (2022). FDA issues revised draft Guidances for Track and Trace. Retrieved July 7, 2024, from https://www.gmp-compliance.org/gmp-news/fda-issues-revised-draft-guidances-for-track-and-trace
European Medicines Agency Official Website. (2019). New safety features for medicines sold in the EU. Retrieved July 7, 2024, from https://www.ema.europa.eu/en/news/new-safety-features-medicines-sold-eu
European Union Intellectual Property Office & Europol. (2022). Intellectual property crime threat assessment 2022. Publications Office of the European Union, Luxembourg. https://www.europol.europa.eu/publications-events/publications/intellectual-property-crime-threat-assessment-2022
Harris, H. (2001). Content analysis of secondary data: A study of courage in managerial decision making. Journal of Business Ethics, 34(3/4), 191–208.
Karunamoorthi, K. (2014). The counterfeit anti-malarial is a crime against humanity: A systematic review of the scientific evidence. Malaria Journal, 13, 209. https://doi.org/10.1186/1475-2875-13-209
Krippendorff, K. (2004). Content analysis: An introduction to its methodology. Sage Publications Inc.
Marcowitz-Bitton, M., Nahmias, Y., & Rozencwaig-Feldman, T. (2022). Parallel import and price regulation in the pharmaceutical market: The Israeli experience. Minnesota Journal of International Law, 31, 111–184.
Mikulic, M. (2023). Total number of counterfeit incidents concerning pharmaceuticals worldwide 2002–2021. Statista. https://www.statista.com/statistics/253150/counterfeit-incidents-concerning-pharamceuticals-since-2002/
Nhu, Q. N. (2011, January 1). Parallel trade of patented pharmaceuticals: A discussion from developing country perspective. Social Science Research Network. https://doi.org/10.2139/ssrn.1767823
OECD/EUIPO. (2020). Trade in counterfeit pharmaceutical products, illicit trade. OECD Publishing, Paris. https://doi.org/10.1787/a7c7e054-en
Odiase, P. O. (2021). Recalibrating African health laws to combat substandard and falsified medical products: Beyond Covid-19. International Journal of Civil Law and Legal Research, 1(2), 1–9. https://www.civillawjournal.com/archives/2021.v1.i2.A.6
Pascu, G. A., Hancu, G., & Rusu, A. (2020). Pharmaceutical serialization, a global effort to combat counterfeit medicines. Acta Marisiensis-Seria Medica, 66(4), 132–139. https://doi.org/10.2478/amma-2020-0028
Pederson, C. (2023). The impact of the exhaustion of rights doctrine on parallel imports and international trade. Indiana Journal of Global Legal Studies, 30(2), 391–415.
Pharmaceutical Services Programme Official Portal. (2021). FarmaTagTM Hologram Security Label. https://pharmacy.moh.gov.my/ms/entri/label-keselamatan-hologram-farmatagtm.html
Pharmaceutical Science Institute Official Portal. (2023). Incident Trends. https://www.psi-inc.org/incident-trends
Pisani, E., Nistor, A. L., Amalia Hasnida, Parmaksiz, K., Xu, J., & Kok, M. O. (2019). Identifying market risk for substandard and falsified medicines: An analytic framework based on qualitative research in China, Indonesia, Turkey and Romania. Wellcome Open Research, 4, 70. https://doi.org/10.12688/wellcomeopenres.15236.1
Rodziah Ahmad. (2002). Parallel importation and compulsory licensing-impact on drug prices in Malaysia [Master’s thesis, Universiti Malaysia Sarawak]. https://ir.unimas.my/id/eprint/16091/
Sale of Drugs Act 1952.
Sweileh, W. M. (2021). Substandard and falsified medical products: Bibliometric analysis and mapping of scientific research. Globalization and Health, 17, 114. https://doi.org/10.1186/s12992-021-00766-5
Tesfaye, W., Abrha, S., Sinnollareddy, M., Arnold, B., Brown, A., Matthew, C., Oguoma, V. M., Peterson, G. M., & Thomas, J. (2020). How do we combat bogus medicines in the age of the COVID-19 pandemic? The American Journal of Tropical Medicine and Hygiene, 103(4), 1360–1363. https://doi.org/10.4269%2Fajtmh.20-0903
White, C. M. (2022). Criminal action against drug counterfeiters: Assessment of the FDA Office of Criminal Investigation Database 2016 through 2021. Annals of Pharmacotherapy, 56(12), 1333–1338. https://doi.org/10.1177/10600280221092482
World Health Organization. (1999). Counterfeit drugs: Guidelines for the development of measures to combat counterfeit drugs. World Health Organization. https://iris.who.int/handle/10665/65892
Zeng, D. Z., & Zhang, B. (2020). Parallel imports in large developing countries. The Annals of Regional Science, 65(2), 509–525. https://doi.org/10.1007/s00168-020-00993-5
Ziavrou, K. S., Noguera, S., & Boumba, V. A. (2022). Trends in counterfeit drugs and pharmaceuticals before and during COVID-19 pandemic. Forensic Science International, 338, 111382. https://doi.org/10.1016/j.forsciint.2022.111382
Zulkifli, N. W., Aziz, N. A., Hassan, Y., Hassali, M. A., Bahrin, N. L. Z., & Ahmad, A. (2016). Are we on the right track?: Overview of unregistered drugs in Malaysia. Journal of Pharmacy Practice and Community Medicine, 2(4), 107–115. https://doi.org/10.5530/jppcm.2016.4.2
Refbacks
- There are currently no refbacks.